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This article is protected by copyright. All rights reserved. secretase genes PSENEN, PSEN1 and NCSTN underlie 0-7% of cases 2, 3 . Gamma-secretase is an intramembranous protease complex comprised of NCSTN, Presenilin, PEN-2 and APH1 involved in regulated intra-membrane proteolysis and the subsequent clearance of substrates from cell membranes (endopeptidase and carboxypeptidase activity). The functional effects of gammasecretase gene mutations in HS are yet to be elicited. It was hypothesised that two previously reported mutations (NCSTN c.1125+1 G>A, PSENEN c.66_67insG) 3 would affect corresponding RNA and protein expression/ function and affect gamma-secretase enzyme activity.
This study was approved by the London Stanmore Research Ethics Committee (11/LO/0966) and conducted in accordance with Declaration of Helsinki principles. Diagnostic criteria are detailed in the supplementary methods. Two 6mm axillary skin biopsies (affected and unaffected skin) were taken from two mutation-positive individuals and three healthy volunteers for immunohistochemistry and cell culture. DNA, RNA and protein was extracted from primary human fibroblasts and analysed via agarose electrophoresis, Sanger sequencing, gene expression assays and immunoblotting . Gamma-secretase enzyme activity assays were performed using a well established in vitro enzyme activity assay (supplementary methods) 4 . Statistical analyses were performed as detailed in supplementary methods.
NCSTN and PSENEN co-localised to the hair follicle, sebaceous gland, apocrine gland, epidermis and inflammatory infiltrates in healthy and mutation-positive human skin (Figs 1, S1, S2). There was no difference in NCSTN or PEN-2 epidermal staining intensity in mutation-positive versus healthy volunteer skin. Antibody specificity was verified using grade IV invasive breast cancer tissue (NCSTN expression is upregulated in invasive ductal breast cancer 5 ) and by showing co-localisation of NCSTN and PEN-2 in healthy skin (replicated using a second NCSTN antibody, Fig. S3 ).
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Agarose electrophoresis and sequencing of the full length NCSTN transcript revealed that NCSTN exon 9 is missing in the NCSTN c.1125+1G>A mutant allele ( Fig. S4 ). NCSTN transcript expression was significantly reduced in mutant versus control primary human fibroblasts ( Fig. S5A, S5B ). An incremental increase in transcript abundance was observed in cycloheximide treated cells over a 24 hour period ( Fig. S5C ), suggesting that the mutant transcript is subject to decay. Immunoblotting revealed a significant corresponding reduction in mature nicastrin expression in mutant versus control fibroblasts (p<0.001, Fig. S6 ), with no additional protein bands to support the presence of a mutant protein (specificity of band validated by siRNA knockdown, Fig. S7 ).
Amplification and direct sequencing of the PSENEN transcript from PSENEN mutant fibroblasts revealed the c.66_67insG insertion (Fig. S8 ). This is predicted to alter the reading frame and result in an altered and elongated PEN-2 protein product (p.Phe23ValfsX98, Fig. S9 ). Transcript and corresponding PEN-2 protein expression was significantly reduced in mutant versus control fibroblasts (p<0.001, Figs. S10, S11). No additional protein bands were identified to support the presence of a mutant protein.
Gamma-secretase enzyme activity assays revealed no difference in the total number of mature gamma-secretase complexes present (assessed by measuring PSEN1-CTF), complex maturity (as measured by the PSEN1-CTF/ PEN-2 ratio), endopeptidase enzyme activity per complex (as measured by the AICD-Flag/ PSEN1-CTF ratio) or carboxypeptidase activity (as measured by the Aβ42:Aβ40 ratio) in NCSTN and PSENEN mutant fibroblasts versus controls (Fig 2) . S20 cells (overexpress gamma-secretase components) acted as a positive control and the gamma-secretase inhibitor L458 acted as a negative control ( Fig S12) 6 . NCSTN and PEN-2 blot densities were calculated from solubilised membrane preparations generated for the enzyme activity assays. In contrast to total cell fractions, there was no significant difference in NCSTN and PEN-2 expression in solubilised membrane fractions harvested from mutant versus control fibroblasts (Fig. S13, Fig. S14 ).
These data demonstrate that the gamma-secretase components NCSTN and PEN-2 are expressed in cutaneous structures that are commonly distorted or altered in HS 7, 8 . The two mutations studied share a downstream pathogenic mechanism of haploinsufficiency (consistent with other globally reported gamma-secretase gene mutations reportedly reducing transcript abundance [9] [10] [11] ). The subsequent total cell reduction in respective protein expression was not, however, replicated in cell membrane preparations. Gamma-secretase protein expression is very tightly regulated 12 , less than 5% of assembled complexes reach the cell membrane. 50% wild type protein may therefore be sufficient to support complex assembly and function. Notch 1, 2 and 3 knockdown in mice results in follicular keratinisation 13 , potentially implicating gamma-secretase-Notch signalling in HS. However, only one of four missense mutations so far reported in HS was found to affect Notch processing 14 , and that effect was negated with heterozygous expression of the mutant allele, again supporting the notion that 50% wild-type protein can maintain enzyme function. It may therefore be postulated that heterozygous mutations in the gamma-secretase genes are not sufficient to cause HS alone. It 
The nature of the globally reported gamma-secretase gene mutations in HS, these data demonstrating haploinsufficiency, and in vivo data showing that NCSTN or PSEN1 knockdown results in the development of follicular keratinisation, follicular atrophy and the formation of epidermal cysts 13, 15, 16 , suggest that a reduction in respective gene product may be involved in the pathogenesis of some cases of HS. Ongoing efforts to elicit the functional consequences of these mutations on gamma-secretase activity and downstream signalling pathways have the potential to identify novel therapeutic targets in this debilitating condition. 
